Translate page

 DSC3535March 2020 - Inlight of the current COVID-19 pandemic we like to keep you updated with the Foundation’s activities and plans that reflect our commitment to the CML community over the coming weeks and months.

Unfortunately we have made the difficult decision to postpone all of the clinical preceptorships planned for the first half of this year and to re-evaluate the remainder in June.

March 2020 - At present we do not have data on CML patients who have been infected with COVID-19. To help gather CML specific information, the iCMLf is collecting details of CML patients diagnosed with COVID-19. 

Please email info@cml-foundation.org with these details.

CoronavirusMarch 2020 - For many people with CML, the reporting on the current public health emergency with the COVID-19 virus, also known as coronavirus, may be a source of anxiety. In light of this, the iCMLf is sharing an expert statement specifically for chronic phase CML patients on the novel coronavirus and the COVID-19 disease.

Please read the full statement below.

We will be keeping you updated as more information becomes available. If you have specific questions please email info@cml-foundation.org. Physicians can post specific patient cases for advice and discussion on the iCMLf clinical case discussion forum.

02 DSC 3070 Kopie

March 2020 - The iCMLf awards the 2020 iCMLf Prize to Dr Sabira Kurtovic, a hematologist at the Clinical Centre of the University of Sarajevo, Bosnia and Herzegovina.

This iCMLf Prize recognises outstanding contributions to the improvement of CML treatment under the challenging conditions of low- and middle-income countries with unequal access to monitoring and treatment. Dr Kurtovic is awarded the iCMLf Prize for her tireless work to ensure that patients with CML in Bosnia and Herzegovina receive the best possible care and have access to treatment with tyrosine kinase inhibitors (TKIs).

"I am thrilled and delighted that Dr Kurtovic will receive the 2020 iCMLf Prize. She has demonstrated a humanitarian spirit and drive through war and beyond, managing always to keep patient welfare at the forefront. Having worked with her I know first hand her dedication, intelligence, and compassion."
(Professor Jerry Radich, Fred Hutchinson Cancer Research Centre)

DSC04074

March 2020 - The iCMLf is pleased to announce the winner of the 2020 Goldman Prize. Professor Jane Apperley, Chair of the Centre for Haematology at Imperial College, London, UK will receive her Goldman medal during the 2020 John Goldman meeting on CML in October. The annual Goldman Prize, awarded in honour of Professor John Goldman, acknowledges outstanding contributions to the management of patients with CML. Professor Apperley receives the prize in recognition of her exceptional reputation as a clinical academic and her many years of expertise in CML and blood and bone marrow transplantation.

"Jane has been one of the leaders in CML research for many years. She has helped us not only develop better therapies for patients with CML, but with thorough, thoughtful and innovative research and analysis, understand the best way to manage patients incorporating all known variables and even helping us think of new variables that play a role. She has always kept a critical but balanced view of the data and performed innovative and groundbreaking research. Jane and her group have been leaders in CML research for many years and her contributions make her a very deserving recipient of this award. And even more fitting having worked with John for so many years.”
(Professor Jorge Cortes, Georgia Cancer Center, Augusta University)

rdd logoFebruary 2020 - Today we join many other organizations supporting rare diseases and patients all over the world to raise awareness for rare diseases. There are over 300 million people living with a rare disease worldwide.

With an incidence of between 1 and 2 people per 100,000 people annually, CML is a rare disease making it even harder for patients living with CML in low- and middle-income countries to be heard and to get access to appropriate monitoring and treatment.